Literature DB >> 10837192

Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance.

S Chakrabarti1, D Pillay, D Ratcliffe, P A Cane, K E Collingham, D W Milligan.   

Abstract

Herpes simplex virus (HSV) infections in 75 allogeneic stem cell transplant recipients were analyzed. Sixteen patients developed HSV disease following transplantation. The risk factors were age, sex (females), unrelated donor graft, and graft-versus-host disease (GVHD) grade >/=2. Seven patients did not respond to acyclovir, and 3 patients failed to respond to foscarnet. Isolates from 4 patients developed resistance to acyclovir/penciclovir, and 3 patients had foscarnet-resistant isolates. The remaining 3 patients failed to respond to acyclovir, despite having sensitive isolates. All the isolates were sensitive to cidofovir, for which the IC(50) values correlated inversely with those for acyclovir (P=.01). The risk factors for clinical resistance to antiviral drugs were a GVHD grade >/=2 (P=.001) and the lack of ganciclovir prophylaxis (P=.01), with a higher nonrelapse mortality in the latter group (P<.0001). Clinical as well as in vitro resistance to antiviral drugs is common in patients with severe GVHD and is associated with a poor outcome.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10837192     DOI: 10.1086/315524

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

Review 1.  Improving the care of patients with genital herpes.

Authors:  S Drake; S Taylor; D Brown; D Pillay
Journal:  BMJ       Date:  2000-09-09

Review 2.  Herpesvirus infections in organ transplant recipients.

Authors:  Frank J Jenkins; David T Rowe; Charles R Rinaldo
Journal:  Clin Diagn Lab Immunol       Date:  2003-01

Review 3.  Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

4.  Characterization of herpes simplex virus type 1 thymidine kinase mutants selected under a single round of high-dose brivudin.

Authors:  Graciela Andrei; Jan Balzarini; Pierre Fiten; Erik De Clercq; Ghislain Opdenakker; Robert Snoeck
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Herpes simplex virus thymidine kinase mutations associated with resistance to acyclovir: a site-directed mutagenesis study.

Authors:  E Frobert; T Ooka; J C Cortay; B Lina; D Thouvenot; F Morfin
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

6.  Delay of alternative antiviral therapy and poor outcomes of acyclovir-resistant herpes simplex virus infections in recipients of allogeneic stem cell transplant - a retrospective study.

Authors:  Ella J Ariza-Heredia; Roy F Chemaly; Lokesh R Shahani; Ying Jang; Richard E Champlin; Victor E Mulanovich
Journal:  Transpl Int       Date:  2018-03-13       Impact factor: 3.782

Review 7.  Antiviral drug resistance: mechanisms and clinical implications.

Authors:  Lynne Strasfeld; Sunwen Chou
Journal:  Infect Dis Clin North Am       Date:  2010-06       Impact factor: 5.982

8.  Genotypic characterization of the DNA polymerase and sensitivity to antiviral compounds of foscarnet-resistant herpes simplex virus type 1 (HSV-1) derived from a foscarnet-sensitive HSV-1 strain.

Authors:  Masayuki Saijo; Tatsuo Suzutani; Shigeru Morikawa; Ichiro Kurane
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

9.  Comparison of Acyclovir and Multistrain Lactobacillus brevis in Women with Recurrent Genital Herpes Infections: a Double-Blind, Randomized, Controlled Study.

Authors:  Amir Hossein Mohseni; Sedigheh Taghinezhad-S; Hossein Keyvani; Narges Ghobadi
Journal:  Probiotics Antimicrob Proteins       Date:  2018-12       Impact factor: 4.609

10.  Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up.

Authors:  C Danve-Szatanek; M Aymard; D Thouvenot; F Morfin; G Agius; I Bertin; S Billaudel; B Chanzy; M Coste-Burel; L Finkielsztejn; H Fleury; T Hadou; C Henquell; H Lafeuille; M E Lafon; A Le Faou; M C Legrand; L Maille; C Mengelle; P Morand; F Morinet; E Nicand; S Omar; B Picard; B Pozzetto; J Puel; D Raoult; C Scieux; M Segondy; J M Seigneurin; R Teyssou; C Zandotti
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.